PROVIDER PROFILE · NPI 1851868392
Shira Lichtman
MEDICARE UTILIZATION · PART B · 2024
No data available for this provider in 2024.
PRESCRIBING · PART D · 2024
Total Rx claims
198
Beneficiaries
—
Total drug cost
$1.9M
Distinct drugs
9
Brand share
78.8%
Top prescribed drugs
Osimertinib Mesylate54 claims
Alectinib Hcl26 claims
Lorlatinib24 claims
Ondansetron22 claims
Rivaroxaban18 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
CROSS-REFERENCE